PQ Bypass, Inc. announces the appointment of medical device executive Stanton J. Rowe to its Board of Directors. As the medical technology company continues to achieve clinical milestones in its development of treatments for long blockages in leg arteries from PAD, expansion of the Board is important to meet the needs for future market expansion and commercialization. Rowe’s experience and expertise will contribute significantly during this critical phase for the company.
Rowe is currently CEO of NXT Biomedical, a medical device incubator funded by Deerfield Capital. He recently retired from Edwards Lifesciences, where he was Chief Scientific Officer since 2008 and also served as Corporate Vice President, Advanced Technology. He joined in 2004 when Edwards acquired Percutaneous Valve Technologies, a company he helped to found in 1999 and where he served as President and CEO. This company developed the first transcatheter aortic valve replacement
“We are pleased to have Stan join our Board; given his extensive experience in emerging technologies, he will provide important insight to the organization during this pivotal time in the company,” said Richard Ferrari, Chairman and CEO of PQ Bypass. “Stan’s experience as both a Chief Executive Officer and Board member of many novel companies will bring immense value as we continue to develop this endovascular approach to helping those suffering from long-lesion peripheral vascular disease.”
Previously, Rowe was Corporate Vice President for Datascope and Vice President at Johnson & Johnson’s Interventional Systems Division (JJIS), responsible for the company’s coronary stent development efforts. At JJIS and the related Cordis Corporation, Rowe held a variety of positions with increasing levels of responsibility, including heading the company’s business development, advanced technology, worldwide clinical research and marketing groups.
“I am looking forward to contributing on the Board to advance this groundbreaking and important technology,” said Rowe. “The PQ Bypass solution has the potential to transform the treatment of long-segment peripheral artery disease, for which there are currently limited viable and durable endovascular options available for patients in need of revascularization. I am pleased to be a part of the team working on this novel approach for this underserved population.”
Rowe is on the Board of Directors of both InSeal Medical, Ltd. and NeuralAnalytics. He is also on the Board of Directors for Orange County’s Discovery Science Center and Sage Hill School, as well as the advisory boards for the Engineering, Business School, and Biomedical Engineering schools at UC Irvine. Rowe received a bachelor’s degree from the University of Alabama.
About PQ Bypass
PQ Bypass, Inc. is a Silicon Valley-based medical device company working to transform the treatment of long-segment peripheral artery disease with minimally invasive endovascular solutions.
PQ Bypass is operated by recognized leaders in the medical device industry including veterans from Medtronic, Abbott, Johnson & Johnson and Stryker. The underlying technology and technique used in the percutaneous DETOUR procedure were co-developed by two world-renowned cardiologists and innovators, Dr. James Joye and Dr. Richard Heuser, who are recognized experts in peripheral artery disease.
The DETOUR™ System is an investigational device and is limited by United States law to investigational use only. It is not available for sale. For more information, please visit www.pqbypass.com.
Chris B. Ernst